Kolexia
Eveillard Jean-Richard Hématologie
Eveillard Jean-Richard
Hématologie
Hôpital Morvan
Brest, France
99 Activités
6 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Lymphomes Paraprotéinémies Macroglobulinémie de Waldenström Thrombocytémie essentielle Thrombocytose Polyglobulie primitive essentielle Polyglobulie

Collaborateurs

Voir plus
Guillerm Gaelle
Guillerm Gaelle
Hôpital Morvan, Brest, France
Dalbies Florence
Dalbies Florence
Hôpital Morvan, Brest, France
Ianotto Jean-Christophe
Ianotto Jean-Christophe
Hôpital Morvan, Brest, France
Berthou Christian
Berthou Christian
Hôpital Morvan, Brest, France

Industries

Voir plus
Janssen
13 collaboration(s)
Dernière en 2023
Amgen
8 collaboration(s)
Dernière en 2023
Novartis
8 collaboration(s)
Dernière en 2022
AstraZeneca
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
CDKN2C Deletion on 1p32 Locus As Part of Irwazh Score, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma
65th ASH Annual Meeting Abstracts   02 novembre 2023
Assessment of the lipemia index determined by the Atellica CH 930 analyzer for the detection of monoclonal immunoglobulins.
Clinical chemistry and laboratory medicine   11 septembre 2023
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study.
Haematologica   31 août 2023
Acquired pseudoxanthoma elasticum-like syndrome and pyruvate kinase deficiency: a case of iron overload?
European journal of dermatology : EJD   21 août 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
MYELOME-PA: Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
Essai Clinique (CHU Nantes)   22 mai 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023
What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
Annual Meeting Abstracts 2022   15 novembre 2022
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022